ArticleThe Journal of biological chemistry2019
An engineered antibody fragment targeting mutant β-catenin via major histocompatibility complex I neoantigen presentation.
Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Dynamic states of an MHC class I molecule during peptide exchange.Nature communications · 2026Article
- Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements.The Journal of clinical investigation · 2026Article
- Structural evolution of polymorphic class I HLA alleles, designating HLA-C with uncertain assemblies.Computational and structural biotechnology journal · 2026Article
- Design of high-specificity binders for peptide-MHC-I complexes.Science (New York, N.Y.) · 2025Article
- Design of high specificity binders for peptide-MHC-I complexes.bioRxiv : the preprint server for biology · 2024Article
- Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.Nature communications · 2023Article
- Rapid Generation and Molecular Docking Analysis of Single-Chain Fragment Variable (scFv) Antibody Selected by Ribosome Display Targeting Cholecystokinin B Receptor (CCK-BR) for Reduction of Chronic Neuropathic Pain.International journal of molecular sciences · 2023Article
- Neoantigens: promising targets for cancer therapy.Signal transduction and targeted therapy · 2023Review
- Cancer Immunotherapy Beyond Checkpoint Blockade:JACC. CardioOncology · 2022Review
- TCR-mimic bispecific antibodies to target the HIV-1 reservoir.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens.Nature communications · 2021Article
- Liquid Biopsy, ctDNA Diagnosis through NGS.Life (Basel, Switzerland) · 2021Review
- Targeting public neoantigens for cancer immunotherapy.Nature cancer · 2021Review
- Targeting loss of heterozygosity for cancer-specific immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Targeting a neoantigen derived from a commonScience (New York, N.Y.) · 2021Article
- Bispecific antibodies targeting mutantScience immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.